Epizyme receives ophran drug designation for EPZ-5676


Epizyme announced that the FDA has granted orphan drug designation for EPZ-5676. Criteria for orphan drug designation requires that the product be intended for treatment of a rare disease or condition, classified as affecting fewer than 200,000 people in the United States.

View Comments (0)